À LA UNE de la Rhumatologie
-
The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register
Psoriatic arthritis (PsA) is an inflammatory arthritis characterised by synovitis, enthesitis, osteitis, and skin and nail disease. There are several phenotypes, including oligoarticular disease, affecting only a few joints, often unilaterally; polyarticular disease, affecting five or more joints, bilaterally; and the severe and destructive, but less common, arthritis mutilans. It has a significant... Lire la suite
BMC Rheumatology 2021; 5(1): 19
-
Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective,...
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that can cause cartilage, bone damage, and disability [1]. The tight control of RA disease activity by following the treat-to-target (T2T) strategy to reach optimal outcomes is thus recommended [2]. Advances in the treatment of RA such as the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs... Lire la suite
BMC Musculoskeletal Disorders 2021; 22(1):...
-
Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic immune-mediated and inflammatory disease characterized by a 48% increased risk of cardiovascular (CV) events and a 50% higher incidence of cardiovascular disease (CVD)-related mortality compared with the general population [1, 2]. There is growing evidence that increased arterial stiffness may account for the excess risk of CVD in RA [3–8]. Arterial stiffness... Lire la suite
Arthritis Research & Therapy 2021; 23(1):...
-
Patient Preference for Treatment Mode of Biologics in Rheumatoid Arthritis: A 2020 Web-based Survey in Japan
Key Summary Points Why carry out this study? Increased use of biologic disease-modifying antirheumatic drugs (bDMARDs) and wider bDMARD options for the treatment of rheumatoid arthritis (RA) may allow physicians to select or switch bDMARDs to better... Lire la suite
Rheumatology and Therapy 2021; aop: 10.1007/s40744-021-00325-9...
- Consultez les archives
